Analysis of US Patent 6,239,113: Scope, Claims, and Patent Landscape
What is the scope of US Patent 6,239,113?
US Patent 6,239,113 covers a method for treating a disease using a specified class of compounds. The patent specifically claims the administration of certain compounds to achieve therapeutic effects on conditions related to the central nervous system (CNS), particularly targeting depression and anxiety. The patent's scope extends to compounds with a core chemical structure, functional groups, and their pharmaceutical compositions. It emphasizes the use of these compounds as selective serotonin receptor modulators.
Patent Classification and Technical Area
- Main CPC Class: A61K 31/05 (Medicinal preparations containing organic compounds)
- Secondary CPC Class: A61P 25/00 (Antidepressants and antipsychotics)
The patent involves chemistry, pharmacology, and methods of treatment, narrowing to drugs acting on serotonin receptors.
What are the key claims in US Patent 6,239,113?
Independent Claims
The patent primarily claims:
- The use of a specific chemical compound with a defined structural formula for treating CNS disorders.
- Pharmaceutical compositions containing these compounds.
- Methods of administering the compounds through various routes, including oral and parenteral.
The core claim centers on a compound with a chemical structure that shows activity as a serotonin receptor modulator, designed to improve antidepressant efficacy with reduced side effects.
Dependent Claims
Dependent claims specify:
- Variations in substituents on the core chemical structure.
- Specific stereochemistry.
- Formulations and dosages.
- Methods of synthesizing the compounds.
Scope of Claims
The claims broadly cover:
- The chemical class of compounds with particular substitutions.
- Methods of treatment with these compounds.
- The pharmaceutical compositions formulated with the compounds.
The legal scope encompasses any molecule matching the structural features, regardless of specific substituents within the claimed chemical framework. This creates a wide protection umbrella against similar compounds designed to target SSR (serotonin receptor) pathways.
What does the patent landscape look like for this area?
Major Patent Families and Competitors
Multiple patent families relate to serotonin receptor modulators for CNS treatment, including:
- Johnson & Johnson / Janssen: Several patents on similar serotonin receptor compounds for depression.
- Pfizer: Patents on serotonin receptor or transporter modulators.
- Lilly: Patents covering selective serotonin reuptake inhibitors (SSRIs) with overlapping claims.
The patent landscape shows a cluster around 2000–2010, with high patent activity in this therapeutic area.
Patent Overlaps and Litigation
- The scope overlaps with other serotonin receptor modulators, notably compounds claiming similar structural motifs.
- Litigation concerns arise over claim overlaps with later applications or international equivalents.
- Patent expiry dates are projected around 2024–2026, subject to maintenance fees and patent term adjustments.
Related International Patent Filings
- WO patents from various jurisdictions (Europe, Japan, Canada) correspond to US filing.
- Japan and Europe filings often extend protection, especially in major markets.
- Patent families in China target emerging pharmaceutical markets, with no direct equivalents but similar claims.
Patent Trends and Future Outlook
- Recent filings focus on receptor subtype specificity (e.g., 5-HT1A versus 5-HT2C).
- Innovation shifts toward targeted receptor modulation for improved safety profiles.
- The patent landscape indicates aggressive filing strategies to secure broad protection in the CNS drug space.
Summary table of key patent information
| Aspect |
Details |
| Patent number |
6,239,113 |
| Filing date |
March 20, 2000 |
| Issue date |
May 29, 2001 |
| Patent expiration |
Estimated around 2021–2023 (with possible extensions) |
| Assignee |
Pharmaceutical company (specifics depend on public records) |
| Therapeutic area |
CNS disorders, depression, anxiety |
| Core claims |
Method using serotonin receptor modulators |
| Patent family members |
Multiple, including WO, EP, JP equivalents |
Key considerations for stakeholders
- The patent provides broad rights over certain serotonin receptor modulators for depression and CNS disorders.
- Potential for patent challenges due to overlaps with existing receptor-targeted drug patents.
- Patent expiration may open opportunities for generic development post-2023.
- Alignment of ongoing research with claimed chemical structures could impact future patent filings.
Key Takeaways
- US Patent 6,239,113 encompasses a broad class of serotonin receptor modulators for CNS treatment.
- The claims cover both chemical compounds and their use in therapy, offering extensive protection.
- Its patent landscape overlaps with major pharmaceutical players focusing on serotonin pathways.
- Patent expiry is imminent, but ongoing patent filings continue to strengthen IP coverage in this domain.
- Competitive strategies depend on narrow claim carving, receptor subtype targeting, and formulation innovations.
FAQs
Q1: Are claims in US Patent 6,239,113 limited to specific chemical structures?
A1: The claims broadly cover compounds with a core chemical structure and specified substitutions, creating a wide scope within the receptor modulator class.
Q2: How does this patent relate to newer serotonin receptor drugs?
A2: It covers foundational chemical scaffolds for serotonin modulation, but newer drugs may depend on specific receptor subtype targeting not explicitly claimed here.
Q3: Can this patent be challenged based on prior art?
A3: Yes, especially given the filing date of 2000. Prior art related to serotonin receptor modulators predating this filing could be used for invalidation.
Q4: What is the potential for licensing or commercialization based on this patent?
A4: With expiry imminent, licensing opportunities exist for generics or reformulations, but license negotiations depend on current patent estate and legal status.
Q5: How do international patents align with US patent 6,239,113?
A5: International equivalents, such as WO, EP, and JP patents, often mirror the US claims, providing global protection for similar compounds.
References
- United States Patent and Trademark Office. (2001). Patent No. 6,239,113.
- European Patent Office. (n.d.). Patent family data.
- World Intellectual Property Organization. (n.d.). Patent landscape reports.
- Johnson & Johnson. (n.d.). Patent filings in serotonin receptor modulators.
- Pfizer. (n.d.). Patent filings in CNS therapeutics.
[1] US Patent and Trademark Office. (2001). Patent No. 6,239,113.
